Patent Eligibility Bill May Carve Out Patenting Of Research

Witnesses at US Senate hearings debate bill's impact on drug pricing; discuss limiting it to medical diagnostics.

Patent Health Care Pharmaceuticals Innovation concept. Copy rights patented certified medicine. - Image

Legislation to expand what inventions may be patented may carve out an exemption for research, one of several potential changes that the US Congress could make to the measure as it seeks to bridge the sharp divide among stakeholders.

The Senate Judiciary's Intellectual Property Subcommittee held hearings June 4 and 5 to get input on the draft bill to...

More from Legislation

EU Ups Ante On Stockpiling For Crises

The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.

Senate Appropriators Give US FDA More Non-User Fee Funds Than House

 

US FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.

EU Medical Countermeasures Strategy Promises More AMR Pull Incentives

 

A new EU strategy to ensure access to essential medicines will boost the development of critical medical counter measures, including vaccines and therapies, according to one pharmaceutical industry group.

EU Health Chief Declares There Is No Better Alternative Than TEVs to Spark Antibiotic Innovation

 

Clarity on what transferable exclusivity vouchers may look like for new antimicrobial drugs could be nearing. Denmark’s new presidency of the Council of the EU has prioritized concluding its negotiations with European Parliament over the legislative overhaul of the EU’s pharmaceutical legislation.

More from Pink Sheet

‘Seize the Moment:’ European Drug Regulators Called To Act On Changes In US

 

European regulators must work hard to maintain and build vital but fragile trust in science and processes, said speakers at an event celebrating the European Medicines 30th anniversary.

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By 

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.

New US FDA Biologics License Pathway Could Be Missing Link To Reduce Animal Testing

 

Akin to the 505(b)(2) NDA, a new biologic pathway could reduce the need for animal testing, FDA toxicologist says. Expanded use of generally accepted scientific knowledge (GASK), which few sponsors have attempted despite a 2023 draft guidance, would also help.